Metformin for the Treatment of mCRC Patients Undergoing FOLFIRI Plus Target Therapy

Other illness

• Subjects who meet any of the following exclusion conditions are not allowed to join the trial
• Known allergy to metformin or any of its components.
• Severe instability in diabetes (ketoacidosis).
• Heart failure, respiratory insufficiency.

Lab values

• Blood sugar level lower than 80 mg/dL
• inadequate hematopoietic function defined as below:
  • hemoglobin \< 9 g/dL;
  • absolute neutrophil count (ANC) \< 1,500/mm3;
  • platelet count \< 100,000/mm3;
• inadequate organ functions defined as below:
  • total bilirubin \> 2 times upper limit of normal (ULN);
  • hepatic transaminases (ALT and AST) \> 2.5 x ULN;
  • creatinine \> 1.5 x ULN;

Other

• Patients other than the above-mentioned main inclusion criteria.
• Non-native speakers

• Aged between 20 and 90 years old
• Patients diagnosed with metastatic colorectal cancer who is going to receive FOLFIRI chemotherapy
• Female must not be planning to become pregnant or breastfeeding, and not pregnant at any point during treatment. (Contraception is required to participate in this trial)
• Those without major physiological diseases (example of major cardiovascular disease is acute myocardial infarction; example of major cerebrovascular disease is acute stroke, malignant hypertension, acute kidney failure, acute liver failure)
• Those who are not allergic to the relevant drugs required for the test
• Those who can follow the doctor's order to take the medicine
• Subjects must be willing to sign the consent form
• Blood sugar level above 80 mg/dL